Protein Loop Grafting to Construct a Variant of Tissue-type Plasminogen Activator That Binds Platelet Integrin αIIbβ3(*)

Protein-protein interactions can be guided by contacts between surface loops within proteins. We therefore investigated the hypothesis that novel protein-protein interactions could be created using a strategy of “loop grafting” in which the amino acid sequence of a biologically active, flexible loop on one protein is used to replace a surface loop present on an unrelated protein. To test this hypothesis we replaced a surface loop within an epidermal growth factor module with the complementarity-determining region of a monoclonal antibody. Specifically, the HCDR3 from Fab-9, an antibody selected to bind the β3-integrins with nanomolar affinity (Smith, J. W., Hu, D., Satterthwait, A., Pinz-Sweeney, S., and Barbas, C. F., III(1994) J. Biol. Chem. 269, 32788-32795), was grafted into the epidermal growth factor-like module of human tissue-type plasminogen activator (t-PA). The resulting variant of t-PA bound to the platelet integrin αIIbβ3 with nanomolar affinity, retained full enzymatic activity, and was stimulated normally by the physiological co-factor fibrin. Binding of the novel variant of t-PA to integrin αIIbβ3 was dependent on the presence of divalent cations and was inhibited by an RGD-containing peptide, demonstrating that, like the donor antibody, the novel t-PA binds specifically to the ligand-binding site of the integrin. These findings suggest that surface loops within protein modules can, at least in some cases, be interchangeable and that phage display can be combined with loop grafting to direct proteins, at high affinity, to selected targets. In principle, these targets could include not only other proteins but also peptides, nucleic acids, carbohydrates, lipids, or even uncharacterized markers of specific cell types, tissues, or viruses.

[1]  D. Cheresh,et al.  Interaction of integrins alpha v beta 3 and glycoprotein IIb-IIIa with fibrinogen. Differential peptide recognition accounts for distinct binding sites. , 1990, The Journal of biological chemistry.

[2]  J. Wells,et al.  A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[3]  B. Keyt,et al.  Making tissue-type plasminogen activator more fibrin specific. , 1993, Protein engineering.

[4]  H Bando,et al.  Expression in E. coli of finger‐domain lacking tissue‐type plasminogen activator with high fibrin affinity , 1985, FEBS letters.

[5]  E. Goldsmith,et al.  Serpin-resistant mutants of human tissue-type plasminogen activator , 1989, Nature.

[6]  J W Smith,et al.  High-affinity self-reactive human antibodies by design and selection: targeting the integrin ligand binding site. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[7]  C. Chothia,et al.  The structure of protein-protein recognition sites. , 1990, The Journal of biological chemistry.

[8]  D. Cheresh,et al.  Purification and functional characterization of integrin alpha v beta 5. An adhesion receptor for vitronectin. , 1990, The Journal of biological chemistry.

[9]  C. Baum,et al.  Potent interleukin 3 receptor agonist with selectively enhanced hematopoietic activity relative to recombinant human interleukin 3. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[10]  E. Haber,et al.  Platelet‐Targeted Fibrinolysis Enhances Clot Lysis and Inhibits Platelet Aggregation , 1991, Circulation.

[11]  D. Henner,et al.  Engineering human prolactin to bind to the human growth hormone receptor. , 1990, Science.

[12]  B. Reavy,et al.  A tissue-type plasminogen activator mutant with prolonged clearance in vivo. Effect of removal of the growth factor domain. , 1988, The Journal of biological chemistry.

[13]  E. Mulvihill,et al.  Fibrin Affinity and Clearance of t-PA Deletion and Substitution Analogues , 1990, Thrombosis and Haemostasis.

[14]  E. Haber,et al.  Innovative approaches to plasminogen activator therapy. , 1989, Science.

[15]  C. Barbas Recent advances in phage display. , 1993, Current opinion in biotechnology.

[16]  M. Alessi,et al.  Fibrinolysis in insulin dependent diabetic patients with or without nephropathy , 1992 .

[17]  J. Scott,et al.  Searching for peptide ligands with an epitope library. , 1990, Science.

[18]  J W Smith,et al.  The Arg-Gly-Asp binding domain of the vitronectin receptor. Photoaffinity cross-linking implicates amino acid residues 61-203 of the beta subunit. , 1988, The Journal of biological chemistry.

[19]  G. Larsen,et al.  Variants of human tissue-type plasminogen activator. Fibrin binding, fibrinolytic, and fibrinogenolytic characterization of genetic variants lacking the fibronectin finger-like and/or the epidermal growth factor domains. , 1988, The Journal of biological chemistry.

[20]  T. Kunkel Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P. Pouwels,et al.  Involvement of finger domain and kringle 2 domain of tissue‐type plasminogen activator in fibrin binding and stimulation of activity by fibrin. , 1986, The EMBO journal.

[22]  J. Sambrook,et al.  Variants of human tissue‐type plasminogen activator that lack specific structural domains of the heavy chain. , 1988, The EMBO journal.

[23]  Jeffrey W. Smith,et al.  The vitronectin receptor alpha v beta 3 binds fibronectin and acts in concert with alpha 5 beta 1 in promoting cellular attachment and spreading on fibronectin , 1990, The Journal of cell biology.

[24]  J. Seidman,et al.  Construction and expression of a recombinant antibody-targeted plasminogen activator. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[25]  E. Madison,et al.  Probing structure-function relationships of tissue-type plasminogen activator by oligonucleotide-mediated site-specific mutagenesis. , 1993, Methods in enzymology.

[26]  M. Smith,et al.  Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template. , 1984, DNA.

[27]  Jeffrey W. Smith,et al.  A mechanism for divalent cation regulation of beta 3-integrins. , 1994, The Journal of biological chemistry.

[28]  E. Goldsmith,et al.  Restoration of serine protease-inhibitor interaction by protein engineering. , 1990, The Journal of biological chemistry.

[29]  E. Ruoslahti,et al.  [27] Arginine-glycine-aspartic acid adhesion receptors , 1987 .

[30]  A. V. van Zonneveld,et al.  Autonomous functions of structural domains on human tissue-type plasminogen activator. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Sambrook,et al.  Tyrosine 67 in the epidermal growth factor-like domain of tissue-type plasminogen activator is important for clearance by a specific hepatic receptor. , 1992, The Journal of biological chemistry.

[32]  M. Matsushima,et al.  Structure of a Conformationally Constrained Arg-Gly-Asp Sequence Inserted into Human Lysozyme (*) , 1995, The Journal of Biological Chemistry.

[33]  P. Hung,et al.  Structure-function analysis with tissue-type plasminogen activator. Effect of deletion of NH2-terminal domains on its biochemical and biological properties. , 1988, The Journal of biological chemistry.

[34]  E. Goldsmith,et al.  Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[35]  N. Go,et al.  Tertiary structure of mouse epidermal growth factor determined by two-dimensional 1H NMR. , 1988, Journal of biochemistry.